Table 2.
The Results of Prognosis Analyses for Overall Survival in Locally Advanced Intrahepatic Cholangiocarcinoma
| Variables | Cox regression Analysis | Competing Risk Regression Analysis | |||||
|---|---|---|---|---|---|---|---|
| Univariate Analysis | Multivariate Analysis | Fine–Gray analysis P value | Multivariate Analysis | ||||
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | ||
| Age (years) | |||||||
| ≤ 65 | Ref. | – | – | – | 0.044 | – | – |
| > 65 | 1.446 (0.928–2.253) | 0.103 | – | – | – | – | |
| Gender | |||||||
| Female | Ref. | – | – | – | 0.299 | – | – |
| Male | 1.193 (0.824–1.726) | 0.351 | – | – | – | – | |
| Liver Cirrhosis | |||||||
| No | Ref. | – | – | – | 0.263 | – | – |
| Yes | 1.31 (0.74–2.32) | 0.354 | – | – | – | – | |
| Unknown | 1.611 (0.904–2.871) | 0.105 | – | – | – | – | |
| Tumor Diameter | |||||||
| ≤ 5cm | Ref. | – | Ref. | – | < 0.001 | Ref. | – |
| > 5cm | 2.523 (1.703–3.738) | < 0.001 | 1.87 (1.215–2.878) | 0.004 | 1.76 (1.066–2.906) | 0.027 | |
| Tumor number | |||||||
| Single | Ref. | – | Ref. | – | < 0.001 | Ref. | – |
| Multiple | 1.969 (1.372–2.826) | < 0.001 | 2.331 (1.592–3.413) | < 0.001 | 1.83 (1.204–2.782) | 0.005 | |
| Grade | |||||||
| Well/Moderate | Ref. | – | – | – | 0.119 | – | – |
| Poor/Undifferentiated | 1.366 (0.932–2.003) | 0.11 | – | – | – | – | |
| MVI | |||||||
| Absence | Ref. | – | – | – | 0.177 | – | – |
| Presence | 1.412 (0.952–2.096) | 0.807 | – | – | – | – | |
| Resection Scope | |||||||
| Minor | Ref. | – | – | – | < 0.001 | – | – |
| Major | 2.131 (1.473–3.082) | < 0.001 | – | – | – | – | |
| Surgical Margin(cm) | |||||||
| (1,+∞) | Ref. | – | Ref. | 0.037 | 0.01 | – | – |
| (0,1) | 1.65 (1.151–2.364) | 0.006 | 1.504 (1.025–2.207) | – | – | ||
| RLNM | |||||||
| Negative | Ref. | – | – | – | < 0.001 | – | – |
| Positive | 2.172 (1.456–3.239) | < 0.001 | – | – | – | – | |
| Adjuvant postoperative therapy | |||||||
| No | Ref. | – | Ref. | – | 0.041 | Ref. | – |
| Yes | 0.618 (0.426–0.898) | 0.012 | 0.532 (0.361–0.784) | 0.001 | 0.585 (0.388–0.884) | 0.011 | |
| CEA | |||||||
| Low | Ref. | – | Ref. | – | < 0.001 | Ref. | – |
| High | 2.129 (1.486–3.05) | < 0.001 | 1.72 (1.161–2.548) | 0.007 | 1.603 (1.029–2.498) | 0.037 | |
| CA19–9 | |||||||
| Low | Ref. | – | Ref. | – | < 0.001 | Ref. | – |
| High | 2.416 (1.674–3.485) | < 0.001 | 1.996 (1.345–2.962) | 0.001 | 2.097 (1.379–3.191) | 0.001 | |
| pCEA | |||||||
| Low | Ref. | – | – | – | 0.037 | – | – |
| High | 1.649 (1.061–2.561) | 0.026 | – | – | – | – | |
| Unknown | 1.567 (0.991–2.478) | 0.055 | – | – | – | – | |
| pCA19–9 | |||||||
| Low | Ref. | – | – | – | 0.001 | – | – |
| High | 2.272 (1.489–3.467) | < 0.001 | – | – | – | – | |
| Unknown | 1.749 (1.086–2.816) | 0.021 | – | – | – | – | |
| SII | |||||||
| Low | Ref. | – | Ref. | – | < 0.001 | Ref. | – |
| High | 2.543 (1.755–3.684) | < 0.001 | 1.99 (1.327–2.986) | 0.001 | 1.934 (1.079–3.465) | 0.027 | |
| AISI | |||||||
| Low | Ref. | – | – | – | < 0.001 | – | – |
| High | 2.004 (1.398–2.871) | < 0.001 | – | – | – | – | |
| SIRI | |||||||
| Low | Ref. | – | – | – | 0.49 | – | – |
| High | 0.927 (0.65–1.322) | 0.675 | – | – | – | – | |
| GPR | |||||||
| Low | Ref. | – | Ref. | – | 0.003 | – | – |
| High | 2.035 (1.414–2.929) | < 0.001 | 1.485 (1.011–2.181) | 0.044 | – | – | |
| PNI | |||||||
| Low | Ref. | – | Ref. | – | < 0.001 | Ref. | – |
| High | 0.349 (0.24–0.506) | < 0.001 | 0.448 (0.306–0.658) | < 0.001 | 0.604 (0.392–0.929) | 0.022 | |
| ALI | |||||||
| Low | Ref. | – | – | – | < 0.001 | – | – |
| High | 0.437 (0.303–0.63) | < 0.001 | – | – | – | – | |
Abbreviations: MVI, microvascular invasion; RLNM, regional lymph node metastasis; CEA, carcino-embryonic antigen; CA19-9, carbohydrate antigen 19–9; pCEA, postoperative CEA; pCA19-9, postoperative CA19-9; SII, systemic immune- inflammation index; AISI, aggregate systemici nflammation index; SIRI, systemic inflammation response index; GPR, gamma-glutamyl- transpeptidase to platelet ratio; PNI, prognostic nutrition index; ALI, advanced lung cancer index.